Bullish
Eli Lilly's stock rises 0.76% to $1,179.27 amid positive clinical trial data.
Eli Lilly's stock price increased by 0.76% to $1,179.27 following the release of promising Phase 3b clinical trial data for its psoriasis and obesity treatments. The data demonstrated significant improvements in patients using the combination of Taltz and Zepbound compared to Taltz alone.
Key points
- New Phase 3b data shows Taltz and Zepbound combination improves psoriasis and obesity treatment outcomes.
- BofA slightly lowers Eli Lilly's price target to $1,341, maintaining a Buy rating.
- Cantor Fitzgerald raises price target to $1,440, keeping an Overweight rating on Eli Lilly.
Sources
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityPR Newswire · October 9, 2026
- Eli Lilly price target lowered to $1,341 from $1,344 at BofATheFly · October 9, 2026
- Eli Lilly price target raised to $1,440 from $1,410 at Cantor FitzgeraldTheFly · October 9, 2026
AI-generated from public news sources. Not financial advice.
